Second malignancies after autologous hematopoietic cell transplantation in children

Bone Marrow Transplantation

Volumn 48, Issue 3, 2013, Pages 363-368

  Danner Koptik, K E ^a   Majhail, N S ^b   Brazauskas, R ^c   Wang, Z ^c   Buchbinder, D ^d   Cahn, J Y ^e   Dilley, K J ^a   Frangoul, H A ^f   Gross, T G ^g   Hale, G A ^h   Hayashi, R J ⁱ   Hijiya, N ^a   Kamble, R T ^j   Lazarus, H M ^k   Marks, D I ^l   Reddy, V ^m   Savani, B N ^f   Warwick, A B ⁿ   Wingard, J R ^o   Wood, W A ^p   Sorror, M L ^q   Jacobsohn, D A ^r   more..

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NATIONAL MARROW DONOR PROGRAM   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^e HÔPITAL MICHALLON   (France)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g NATIONWIDE CHILDREN S HOSPITAL   (United States)

^h JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j CENTER FOR CELL AND GENE THERAPY   (United States)

^k UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^l BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^m Florida Center for Cellular Therapy   (United States)

ⁿ UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^o UNIVERSITY OF FLORIDA   (United States)

^p UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^q USA   (United States)

^r CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

autologous; hematopoietic cell transplantation; pediatric; risk factors; second cancers

Indexed keywords

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; FEMALE; FOLLOW UP; HUMAN; INFANT; KAPOSI SARCOMA; LIVER CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEPHROBLASTOMA; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARYNX CANCER; PRIORITY JOURNAL; SARCOMA; SCHOOL CHILD; SECOND CANCER; SOFT TISSUE CANCER; TESTIS CANCER; THYROID CANCER; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; INFANT; MALE; NEOPLASMS, SECOND PRIMARY; RISK FACTORS; SURVIVORS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84875231046     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.166     Document Type: Article

References (25)

1. Matthay KK. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant 1999; 3(Suppl 1): 72-77.
2. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002; 20: 2284-2292.
3. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol 1996; 14: 2417-2426.
4. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE et al. Risk-Adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7: 813-820.
5. Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 2004; 22: 4532-4540.
6. Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M. Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer 2007; 49: 196-198.
7. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102: 1083-1095.
8. Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27: 2356-2362.
9. Meadows AT, Baum E, Fossati-Bellani F, Green D, Jenkin RD, Marsden B et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol 1985; 3: 532-538.
10. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lym-phoblastic leukemia. JAMA 2007; 297: 1207-1215.
11. Walter AW, Hancock ML, Pui CH, Hudson MM, Ochs JS, Rivera GK et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol 1998; 16: 3761-3767.
12. Curtis RE, Metayer C, Rizzo JD, Socie G, Sobocinski KA, Flowers ME et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105: 3802-3811.
13. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
14. Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011; 117: 316-322.
15. Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175-1183.
16. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet 2002; 359: 1309-1310.
17. Klein J, Moeschberger M. Survival analysis: techniques of censored and truncated Data. 2nd edn. Springer-Verlag: New York, 2003.
18. Kaplan EL, Meier P. Nonparametric estimation from in complete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-202.
20. Breslow NE, Day NE. The design and analysis of cohort studies. In: Heseltine E (ed.), Statistical Methods in Cancer Research. Vol II. International Agency for Research on Cancer Scientific Publications No. 82: Lyon, France, 1987.
21. Preston DL, Lubin JH, Pierce DA. Epicure User's Guide. Hirosoft International: Seattle, WA, 1993.
22. Curado MP, Edwards B, Shin HR et al. Cancer Incidence in Five Continents. Vol IX. International Agency for Research on Cancer Scientific Publications No. 160: Lyon, France, 2007.
23. Horner MJ, Ries LAG, Krapcho M et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute, Bethesda, MD. In: http://seer.cancer.gov/ 1975-2006/based on November 2008 SEER data submission, posted to the SEER web site, 2009.
24. Nottage K, Lanctot J, Li Z, Neglia JP, Bhatia S, Hammond S et al. Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study. Blood 117: 6315-6318.
25. Hake CR, Graubert TA, Fenske TS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant 2007; 39: 59-70.